Dengue Fever and Dengue Haemorrhagic Fever
Dengue is regarded as one of the most important arboviral infections in the world. Dengue fever (DF), including its variants, dengue haemorrhagic fever (DHF) and dengue shock syndrome (DSS), is caused by four antigenically distinct but related dengue viruses (DENV-1, DENV-2, DENV-3 and DENV-4), also known as serotypes, belonging to genus Flavivirus, family Flaviviridae. There exists a considerable variation within each serotype in the form of phylogenetically distinct subtypes or genotypes. Currently, each serotype has subtype/genotype as follows: • DENV-1: Three • DENV-2: Two (one is found in non-human primates) • DENV-3: Four • DENV-4: Four (one is found in non-human primates)
There is a major concern on increase of dengue in Asia Pacific during the past decade. The WHO South-East Asia Region together with Western Pacific Region bears more than 70% of the global burden. The use of standard guidelines produced by WHO has helped in reduction of case fatality rates. As recommended by the last meeting of the Regional Technical Advisory Group for dengue in November 2012 at Bali, Indonesia , an expert consultation was organized in Colombo, Sri Lanka from 12th to 14th August 2013; to synchronize the WHO 1997 (WHO-SEARO 2011 revised) guidelines and WHO-TDR 2009 guidelines. The Expert consultation recommended to harmonize the 1997 WHO classification (2011 WHO/SEARO revised guidelines) with the WHO-TDR 2009 classification by addressing the plasma leakage (1997) as the major pathophysiology that may lead to severe disease first.
Regional Programme Review Group meeting for Lymphatic Filariasis Elimination, Dili, Timor-Leste, 25-27 June 2013
The 10th meeting of the Regional Programme Review Group (RPRG) for elimination of lymphatic filariasis (LF) was held in Dili, Timor Leste from 25th to 27th June 2013. This was attended by the members of RPRG, representatives from Centre for Neglected Tropical Diseases, Liverpool; and Glaxo-Smith-Klein (GSK). The Group reviewed the progress made by the LF endemic Member States of WHO SEA Region and requirement of Albendazole tablets (one of the drugs of the mass drug administration) for the year 2013.
2 December 2012
27 November 2012
27 November 2012
Dr Ahmed Jamsheed Mohamed
World Health Organization
Regional Office for South-East Asia
World Health House
Mahatma Gandhi Marg
New Delhi 110 002, India
Telephone: +91-11-23370804, 23370809-11